Bridging with a limited RT field in a CAR T-cell patient. (A) PET-CT scout image before CAR T-cell therapy in a male patient with primary refractory DLBCL. He presented 1 month after the illustrated PET-CT scan with severe abdominal pain, prompting CT imaging that revealed increased infiltrative soft tissue masses in the abdomen and pelvis (not shown). (D) Emergent RT was initiated with an intensity-modulated RT (IMRT) plan to the sites of symptomatic disease to an intended dose of 36 Gy; however, only 10.8 Gy was administered. (E) The IMRT plan fused to the sagittal pre–CAR T-cell PET-CT scan illustrates the sites of mediastinal and pelvic disease (arrows) that were excluded from the RT field. (B) The 30-day post–axi-cel PET-CT scan revealed PR to therapy, with a score of 4 on a 5-point scale. The 90-day post–CAR T-cell PET-CT scan (C) revealed new sites of disease progression outside of the RT field, as illustrated by the day-90 CT (F) and PET-CT (G) scans fused to the pre–CAR T-cell RT plan, with the arrows indicating the sites of disease progression outside of the RT field that were present before CAR T-cell therapy.